Literature DB >> 21769816

Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score.

Jingjin Che1, Guangping Li, Weiding Wang, Qiang Li, Hongtao Liu, Kangyin Chen, Tong Liu.   

Abstract

BACKGROUND: The relationship between autoantibodies against human oxidized low-density lipoprotein (anti-oxLDL) and the progression of atherosclerotic diseases is unclear. This study aimed to investigate the association between serum anti-oxLDL titers and the severity and extent of coronary stenotic lesions.
METHODS: We measured the titers of IgG anti-oxLDL by enzyme-linked immunosorbent assay (ELISA) in 154 consecutive patients undergoing coronary angiography for suspected coronary heart disease (CHD). The severity and extent of coronary stenotic lesions were evaluated on coronary angiography findings by Gensini score.
RESULTS: The anti-oxLDL titers were significantly lower in 117 patients with CHD than those in 37 controls (p<0.01). The serum anti-oxLDL titers were significantly correlated to serum levels of globulin (r = 0.405), conjugated bilirubin (r = 0.280), high-density lipoprotein (HDL) cholesterol (r = 0.238), homeostatic model assessment for insulin resistance (HOMA-IR) (r = -0.267), high sensitivity C-reactive protein (hs-CRP) (r = -0.230), triglyceride (r = -0.207), advanced glycation end products (AGEs) (r = -0.200), and malondialdehyde (r = -0.165). However, only HDL cholesterol and AGEs remained independent predictors of the anti-oxLDL titers after adjusting for confounders. Multivariate regression analysis showed that the anti-oxLDL titers, as well as serum levels of hs-CRP, fasting glucose, and albumin, were significantly associated with Gensini scores.
CONCLUSIONS: Titers of anti-oxLDL are inversely associated with complicated proatherogenic metabolic risk factors, and the severity of coronary stenotic lesions calculated by Gensini scores, supporting a protective role for anti-oxLDL against the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769816

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  10 in total

1.  Antibody to oxidized low-density lipoprotein inhibits THP1 cells from apoptosis by suppressing NF-κB pathway activation.

Authors:  Rui Dai; Jing Dong; Weijuan Li; Yi Zhou; Wei Zhou; Wenping Zhou; Manhua Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-08

2.  Detection of circulating IgG antibodies to apolipoprotein B100 in acute myocardial infarction.

Authors:  Xueying Zhang; Xiaohong Zhang; Mingming Lei; Yingzi Lin; Ian L Megson; Jun Wei; Bo Yu; Yuanzhe Jin
Journal:  FEBS Open Bio       Date:  2015-08-11       Impact factor: 2.693

3.  Investigation of serum oxidized low-density lipoprotein IgG levels in patients with angiographically defined coronary artery disease.

Authors:  Mohsen Moohebati; Vahid Kabirirad; Majid Ghayour-Mobarhan; Habibollah Esmaily; Shima Tavallaie; Amir Akhavan Rezayat; Hossein Pourghadamyari; Amirhossein Sahebkar
Journal:  Int J Vasc Med       Date:  2014-02-03

4.  Cystamine attenuates lupus-associated apoptosis of ventricular tissue by suppressing both intrinsic and extrinsic pathways.

Authors:  Bor-Show Tzang; Tsai-Ching Hsu; Cheng-Yi Kuo; Tzy-Yen Chen; Szu-Yi Chiang; Sin-Lun Li; Shao-Hsuan Kao
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

5.  Association of Serum Prealbumin with Angiographic Severity in Patients with Acute Coronary Syndrome.

Authors:  Chenglong Zhang; Pei Liu; Ke Xia; Han Fang; Minna Jiang; Qiying Xie; Zaixin Yu; Tianlun Yang
Journal:  Med Sci Monit       Date:  2017-08-21

6.  The expression level of miR-155 in plasma and peripheral blood mononuclear cells in coronary artery disease patients and the associations of these levels with the apoptosis rate of peripheral blood mononuclear cells.

Authors:  Duo Zhao; Jing Zhao; Jiangbin Sun; Yanling Su; Jinfeng Jian; Huaan Ye; Jiawang Lin; Zongda Yang; Jiatao Feng; Zhiping Wang
Journal:  Exp Ther Med       Date:  2018-09-26       Impact factor: 2.447

7.  Antioxidized LDL antibodies are associated with different metabolic pathways in patients with atherosclerotic plaque and type 2 diabetes.

Authors:  M Rosa Bernal-Lopez; Lourdes Garrido-Sanchez; Victor Gomez-Carrillo; Jose Luis Gallego-Perales; Vicenta Llorente-Cortes; Fernando Calleja; Ricardo Gomez-Huelgas; Lina Badimon; Francisco J Tinahones
Journal:  Diabetes Care       Date:  2012-11-27       Impact factor: 19.112

8.  Using oxidized low-density lipoprotein autoantibodies to predict restenosis after balloon angioplasty in patients with acute myocardial infarction.

Authors:  Ching-Hui Huang; Chia-Chu Chang; Ching-Shan Huang; Chen-Ling Kuo; Ching-Pei Chen; Chien-Hsun Hsia; Yung-Ming Chang; Hung-Te Chen; Chih-Chung Feng; Lee-Shin Lin; Po-Ta Yang; Chen-Dao Tsai; Chih-Sheng Lin; Chin-San Liu
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

Review 9.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

Review 10.  Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review.

Authors:  Victor J van den Berg; Maxime M Vroegindewey; Isabella Kardys; Eric Boersma; Dorian Haskard; Adam Hartley; Ramzi Khamis
Journal:  Antioxidants (Basel)       Date:  2019-10-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.